Cord Blood Transplant for Children and Young Adults with Blood Cancers and Non-Cancerous Disorders

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT04644016

This study is exploring the use of cord blood transplants in children and young adults with serious blood cancers and other life-threatening blood disorders who do not have a suitable donor for a traditional transplant.

Patient Parameters

Program Overview

This clinical trial is focused on using cord blood transplants to treat children and young adults with severe blood cancers and non-cancerous blood disorders. The study aims to understand the safety and effectiveness of this treatment in patients who do not have a matched donor for a traditional bone marrow transplant. Cord blood, which is collected from the umbilical cord after birth, is used because it can be a good alternative when a suitable donor is not available.

Eligibility Criteria

Inclusion Criteria

  • Children and young adults aged 21 or younger without a suitable donor for a traditional transplant.
  • Diagnosed with certain types of blood cancers like acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) at high risk of returning or not responding to treatment.
  • Diagnosed with other blood disorders like myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD) that are life-threatening.
  • Diagnosed with high-risk non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) that is not in remission.
  • Diagnosed with certain inherited metabolic disorders early in the disease, such as Hurler Syndrome or Metachromatic Leukodystrophy.
  • Diagnosed with non-cancerous blood disorders like hemoglobinopathies or bone marrow failure syndromes.
  • Must have good organ function and be in relatively good health, with specific blood and organ function levels.
  • Must meet specific criteria for cord blood transplant, including matching and cell count requirements.

Exclusion Criteria

  • Poor overall health or organ function.
  • Advanced metabolic disease.
  • Active leukemia in the central nervous system.
  • Progression of indolent NHL or Hodgkin lymphoma after recent treatment.
  • Diagnosed with myelofibrosis or other cancers with significant bone marrow issues.
  • Recent autologous stem cell transplant within the last 6 months.
  • Previous allogeneic stem cell transplant.
  • Active and uncontrolled infections at the time of transplant.
  • HIV infection or positive for HTLV-1.
  • Pregnant or breastfeeding.
  • Unable to provide informed consent or follow the treatment plan.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.